Trial · NCT04740931
Outcomes48
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 48
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | From Baseline through Week 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
| SECONDARY | Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
| SECONDARY | Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24 | From Baseline through Week 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | microns | MEAN |
| SECONDARY | Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | Percentage of participants | NUMBER |
| SECONDARY | Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24 | Baseline and Week 24 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. Only participants with non-missing Baseline and Week 24 assessments were included for analysis. | score on a scale | MEAN |
| SECONDARY | Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72 | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72 | Intent-to-Treat (ITT) Population: all participants who were randomized in the study, grouped according to the treatment assigned at randomization. | ETDRS Letters | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04740931/outcomes